SUNScholar
⇒
General Collections
⇒
SUNScholar - Work in Progress
⇒
Stellenbosch University - Scopus Publications
⇒
Browsing by Subject

Subject

Now showing items 1-6 of 6

Cardiac dysrhythmias associated with intravenous lorazepam, diazepam, and midazolam during oral surgery

Roelofse J.A. Van der Bijl P. (1994)

The incidence and nature of cardiac dysrhythmias occurring during intravenous sedation with lorazepam, diazepam, and midazolam for oral surgery were studied. Sixty American Society of Anesthesiologists (ASA) I patients of ...
Catecholamine-cAMP induces arrhythmias in the infarcting pig heart

Podzuweit T. Els D.J. Shanley B.C. (1978)

[No abstract available]
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 52-week open-label studies

Emsley R. Berwaerts J. Eerdekens M. Kramer M. Lane R. Lim P. Hough D. Palumbo J. (2008)

Long-term efficacy and safety of paliperidone extended-release tablets (3-12 mg/day) were evaluated in pooled data from 52-week open-label extension (OLE) phases of three 6-week, placebo-controlled, double-blind (DB) trials ...
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study

Davidson M. Emsley R. Kramer M. Ford L. Pan G. Lim P. Eerdekens M. (2007)

Background: Paliperidone extended-release tablet (paliperidone ER) is an oral psychotropic agent developed for schizophrenia treatment. Paliperidone (9-OH-risperidone, metabolite of risperidone), when used with OROS ...
Reboxetine and citalopram in panic disorder: A single-blind, cross-over, flexible-dose pilot study

Seedat S. Van Oudtshoorn E.V.R. Muller J.E. Mohr N. Stein D.J. (2003)

Both noradrenergic and serotonergic systems have been implicated in the pathophysiology of panic disorder. The advent of selective serotonin (5-HT) reuptake inhibitors (SSRIs) (e.g. citalopram) and, more recently, selective ...
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge

Louw C. Williams Z. Venter L. Leichtl S. Schmid-Wirlitsch C. Bredenbroker D. Bardin P.G. (2007)

Background: Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, is currently in clinical development for the treatment of asthma. Objectives: This pilot study examined the effect of roflumilast on allergen-induced ...